Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as LY4064809
LY4064809 Test Formulation · 1 trial · 1 indication
PK: Cmax of LY4064809
PK: AUC of LY4064809
| Arm | Type | Description |
|---|---|---|
| LY4064809 Test | EXPERIMENTAL | LY4064809 test (Phase 3 formulation) formulation administered orally in one of two periods. |
| LY4064809 Reference | EXPERIMENTAL | LY4064809 reference (Phase 1 formulation) formulation administered orally in one of two periods. |
| Name | Type | Description |
|---|---|---|
| LY4064809 Test Formulation | DRUG | Administered orally |
| LY4064809 Reference Formulation | DRUG | Administered orally |
Inclusion Criteria: * Are healthy as determined by medical evaluation, including medical history, physical examination, vital signs, and electrocardiogram (ECG) at screening and admission. * Have clinical laboratory test results within the normal range * Have normal blood pressure and pulse rate or...
LY4064809, also known as tersolisib, is an investigational small molecule being studied for the treatment of advanced breast cancer with a PIK3CA genetic change. It is being evaluated in combination with other anti-cancer treatments in a Phase 3 clinical trial enrolling participants with breast neoplasms and metastasis.
LY4064809 targets the PIK3CA gene. It is being studied in patients whose tumors carry a PIK3CA genetic change, as part of a Phase 3 trial for advanced breast cancer. The drug is designed to act on this specific genetic alteration.
LY4064809 is being developed by Eli Lilly and Company, a pharmaceutical company listed on the stock exchange under the ticker LLY. The drug is also known as tersolisib and is currently in clinical development for oncology indications.
LY4064809 is in Phase 3 clinical development for advanced breast cancer with a PIK3CA genetic change. It is an investigational drug and has not been approved by regulatory authorities. Earlier Phase 1 studies in healthy participants have been completed.
LY4064809 is being studied in a Phase 3 trial, NCT07174336, which is recruiting 800 participants with advanced breast cancer and PIK3CA mutations across multiple countries. Additional Phase 1 studies in healthy participants, including NCT07247357, NCT07339735, and NCT07519525, have been completed.
Yes, LY4064809 is also known as tersolisib. The Phase 3 clinical trial for advanced breast cancer refers to the drug as tersolisib (LY4064809/STX-478). Both names refer to the same investigational small molecule being developed by Eli Lilly and Company.